Sobre 4 señales de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Browse the detailed record of transactions filed by Gordon Carl l, Consejero. Director active across 11 companies, notably Theseus Pharmaceuticals, Inc.. Aggregated, 36 disclosures have been published. Breakdown: 18 buys · 3 sells. Total volume traded: €58m. History available since 4 November 2021. The latest transaction was disclosed on 10 August 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Gordon Carl l
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
137.931 títulos@ 7,25 US$13.1% de su flujoCommon StockSEC:0000947871-22-001259:0
Salida canónica: 23 mar 2023 (T+90)
25 de 36 declaraciones
About Gordon Carl l
GORDON CARL L is Administrateur and has filed 31 disclosures. In the sampled recent filings, buys total 21844360 EUR and sells total 16530348 EUR, over the period from 2021-10-14 to 2025-12-18. He appears as a director of Theseus Pharmaceuticals, Inc., Compass Therapeutics, Inc., Adicet Bio, Inc., Kinnate Biopharma Inc., Keros Therapeutics, Inc. and Terns Pharmaceuticals, Inc.